GOETTINGEN, Germany - Friday, June 3rd 2016 [ME NewsWire]
(BUSINESS WIRE)-- As approved by the Annual Shareholders’ Meeting of Sartorius AG (FWB:SRT) on April 7, the capital increase by use of retained earnings to perform a stock split will be implemented on June 13, 2016. Every shareholder will receive three additional shares of the same type per share held, without an additional payment. The stock split is intended to encourage trading with Sartorius shares and make them attractive to even broader groups of investors.
Following implementation of the stock split, the share capital of Sartorius AG will be divided into 37,440,000 ordinary shares and 37,440,000 preference shares.
Upcoming Financial Dates
July 25, 2016
Publication of first-half figures (January to June 2016)
October 24, 2016
Publication of nine-month figures (January to September 2016)
This press release contains statements about the future development of the Sartorius Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.
A Profile of Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.1 billion euros in 2015. Around 6,200 people work for the Group, which has its own manufacturing and sales sites in around 110 countries.
Petra Kirchhoff, +49 (0)551.308.1686
Vice President Corporate Communications
Andreas Theisen, +49 (0)551.308.1668
Director, Investor Relations